Different Paths and Potentials to Harm Reduction in Different Welfare States: Drug Consumption Rooms in the United Kingdom, Denmark, and France

Overview

Journal Am J Public Health

Specialty Public Health

Date 2022 Mar 29

PMID 35349322

Authors

Marie Jauffret-Roustide

Esben Houborg

Matthew Southwell

Daphne Chronopoulou

Jean-Maxence Granier

Vibeke Asmussen Frank

Alex Stevens

Tim Rhodes

Affiliations

Soon will be listed here.

Citing Articles

Who is the drug user activist?: recounting the conceptualisation of drug user activism in the United Kingdom.

Naguit R, Schlossenberg S, Fernes P Harm Reduct J. 2024; 21(1):212.

PMID: 39609692 PMC: 11606087. DOI: 10.1186/s12954-024-01128-1.

International harm reduction indicators are still not reached: results from a repeated cross-sectional study on drug paraphernalia distribution in Germany, 2021.

Hommes F, Krings A, Dorre A, Neumeier E, Schaffer D, Zimmermann R Harm Reduct J. 2023; 20(1):137.

PMID: 37726726 PMC: 10507885. DOI: 10.1186/s12954-023-00870-2.

'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England.

Riley F, Harris M, Poulter H, Moore H, Ahmed D, Towl G Harm Reduct J. 2023; 20(1):66.

PMID: 37173697 PMC: 10182620. DOI: 10.1186/s12954-023-00785-y.

A cultural and political difference: comparing the racial and social framing of population crack cocaine use between the United States and France.

Goulian A, Jauffret-Roustide M, Dambele S, Singh R, Fullilove 3rd R Harm Reduct J. 2022; 19(1):44.

PMID: 35550157 PMC: 9096779. DOI: 10.1186/s12954-022-00625-5.

References

Ashton J, Seymour H . Public Health and the origins of the Mersey Model of Harm Reduction. Int J Drug Policy. 2010; 21(2):94-6. DOI: 10.1016/j.drugpo.2010.01.004. View

Jauffret-Roustide M, Pedrono G, Beltzer N . Supervised consumption rooms: the French Paradox. Int J Drug Policy. 2013; 24(6):628-30. DOI: 10.1016/j.drugpo.2013.05.008. View

Ibragimov U, Young A, Cooper H . Understanding rural risk environments for drug-related harms: Progress, challenges, and steps forward. Int J Drug Policy. 2020; 85:102926. PMC: 8215764. DOI: 10.1016/j.drugpo.2020.102926. View

Collins A, Boyd J, Cooper H, McNeil R . The intersectional risk environment of people who use drugs. Soc Sci Med. 2019; 234:112384. PMC: 6719791. DOI: 10.1016/j.socscimed.2019.112384. View

Rhodes T, Kimber J, Small W, FitzGerald J, Kerr T, Hickman M . Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction. 2006; 101(10):1384-93. DOI: 10.1111/j.1360-0443.2006.01556.x. View

Hutcheon J, Harper S . No, it is not too good to be true: Response by Hutcheon and Harper. Paediatr Perinat Epidemiol. 2021; 35(6):781-782. DOI: 10.1111/ppe.12802. View

Marshall B, Milloy M, Wood E, Montaner J, Kerr T . Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011; 377(9775):1429-37. DOI: 10.1016/S0140-6736(10)62353-7. View

Harris M, Rhodes T . Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'. Int J Drug Policy. 2012; 24(6):e43-50. DOI: 10.1016/j.drugpo.2012.10.003. View

Friedman S, Des Jarlais D, Sotheran J, Garber J, Cohen H, Smith D . AIDS and self-organization among intravenous drug users. Int J Addict. 1987; 22(3):201-19. DOI: 10.3109/10826088709027425. View

10.

Kerr T, Mitra S, Kennedy M, McNeil R . Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017; 14(1):28. PMC: 5437687. DOI: 10.1186/s12954-017-0154-1. View

11.

Atkinson A, McAuley A, Trayner K, Sumnall H . 'We are still obsessed by this idea of abstinence': A critical analysis of UK news media representations of proposals to introduce drug consumption rooms in Glasgow, UK. Int J Drug Policy. 2019; 68:62-74. DOI: 10.1016/j.drugpo.2019.03.010. View

12.

Milloy M, Kerr T, Tyndall M, Montaner J, Wood E . Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One. 2008; 3(10):e3351. PMC: 2556397. DOI: 10.1371/journal.pone.0003351. View

13.

Finch E . IJDP editorial from harm to hope - A 10-year drugs plan to cut crime and save lives. HM Government 2021. Int J Drug Policy. 2022; 109:103840. DOI: 10.1016/j.drugpo.2022.103840. View

14.

Jauffret-Roustide M, Cailbault I . Drug consumption rooms: Comparing times, spaces and actors in issues of social acceptability in French public debate. Int J Drug Policy. 2018; 56:208-217. DOI: 10.1016/j.drugpo.2018.04.014. View

15.

Dennis F, Rhodes T, Harris M . More-than-harm reduction: Engaging with alternative ontologies of 'movement' in UK drug services. Int J Drug Policy. 2020; 82:102771. DOI: 10.1016/j.drugpo.2020.102771. View

16.

Southwell M, Shelly S, Macdonald V, Verster A, Maher L . Transforming lives and empowering communities: evidence, harm reduction and a holistic approach to people who use drugs. Curr Opin HIV AIDS. 2019; 14(5):409-414. DOI: 10.1097/COH.0000000000000566. View

17.

Rhodes T . Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009; 20(3):193-201. DOI: 10.1016/j.drugpo.2008.10.003. View

18.

Dennis F . Drug fatalities and treatment fatalism: Complicating the ageing cohort theory. Sociol Health Illn. 2021; 43(5):1175-1190. PMC: 7611256. DOI: 10.1111/1467-9566.13278. View

19.

Frank V, Anker J, Tammi T . Drug user organizations in the Nordic countries--local, national, and international dimensions. Subst Use Misuse. 2012; 47(5):462-73. DOI: 10.3109/10826084.2012.644095. View

20.

Salmon A, van Beek I, Amin J, Kaldor J, Maher L . The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction. 2010; 105(4):676-83. DOI: 10.1111/j.1360-0443.2009.02837.x. View